Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
Public ClinicalTrials.gov record NCT04624204. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants With Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Researchers are looking for new ways to treat Limited-Stage Small Cell Lung Cancer (LS-SCLC), a type of lung cancer that has not spread from the lung to other parts of the body. The purpose of this study is to learn if pembrolizumab and olaparib, when given with chemotherapy and radiation treatment (CRT), can be effective in treating LS-SCLC. The researchers want to know if participants who receive CRT and pembrolizumab, with or without olaparib, have a longer overall survival compared to participants who only receive CRT.
Study identification
- NCT ID
- NCT04624204
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 672 participants
Conditions and interventions
Conditions
Interventions
- Pembrolizumab 200 mg Biological
- Pembrolizumab 400 mg Biological
- Pembrolizumab placebo (saline) Drug
- Olaparib 300 mg BID Drug
- Olaparib matching placebo Drug
- Etoposide 100 mg/m^2 Drug
- Platinum, investigator's choice Drug
- Standard Thoracic Radiotherapy Radiation
- Prophylactic Cranial Irradiation (PCI) Radiation
Biological · Drug · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 8, 2020 (Actual)
- Primary completion
- Oct 28, 2027 (Estimated)
- Completion
- Nov 15, 2027 (Estimated)
- Last update posted
- Sep 24, 2026
2020 – 2027
United States locations
- U.S. sites
- 35
- U.S. states
- 20
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ironwood Cancer & Research Centers ( Site 0007) | Chandler | Arizona | 85224 | — |
| Loma Linda University Cancer Center ( Site 0011) | Loma Linda | California | 92350 | — |
| Georgetown University ( Site 0017) | Washington D.C. | District of Columbia | 20007 | — |
| Moffitt Cancer Center ( Site 0137) | Tampa | Florida | 33612 | — |
| University of Chicago Medical Center ( Site 0136) | Chicago | Illinois | 60637 | — |
| Fort Wayne Medical Oncology and Hematology ( Site 0034) | Fort Wayne | Indiana | 46804 | — |
| University of Kentucky Chandler Medical Center ( Site 0138) | Lexington | Kentucky | 40536 | — |
| Overton Brooks VAMC ( Site 0041) | Shreveport | Louisiana | 71101 | — |
| Harry & Jeanette Weinberg Cancer Institute ( Site 0045) | Baltimore | Maryland | 21237 | — |
| VA Ann Arbor Healthcare System ( Site 0050) | Ann Arbor | Michigan | 48105 | — |
| St. Vincent Healthcare Frontier Cancer Center ( Site 0056) | Billings | Montana | 59102 | — |
| Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0061) | Omaha | Nebraska | 68130 | — |
| Memorial Sloan Kettering - Basking Ridge ( Site 0133) | Basking Ridge | New Jersey | 07920 | — |
| John Theurer Cancer Center ( Site 0064) | Hackensack | New Jersey | 07601 | — |
| Memorial Sloan Kettering - Monmouth ( Site 0135) | Middletown | New Jersey | 07748 | — |
| Memorial Sloan Kettering - Bergen ( Site 0130) | Montvale | New Jersey | 07645 | — |
| Rutgers Cancer Institute of New Jersey ( Site 0123) | New Brunswick | New Jersey | 08901 | — |
| Memorial Sloan Kettering- Commack ( Site 0132) | Commack | New York | 11725 | — |
| Memorial Sloan Kettering - Westchester-Thoracic Oncology ( Site 0134) | Harrison | New York | 10604 | — |
| Memorial Sloan Kettering Cancer Center ( Site 0069) | New York | New York | 10021 | — |
| Memorial Sloan Kettering - Nassau ( Site 0131) | Uniondale | New York | 11553 | — |
| Fairview Hospital-Moll Cancer Center ( Site 0141) | Cleveland | Ohio | 44111 | — |
| Cleveland Clinic Main ( Site 0139) | Cleveland | Ohio | 44195 | — |
| Cleveland Clinic - Hillcrest Hospital-Hillcrest Hospital Cancer Center ( Site 0140) | Mayfield Heights | Ohio | 44124 | — |
| Penn State Hershey Cancer Institute ( Site 0081) | Hershey | Pennsylvania | 17033 | — |
| Saint Francis Cancer Center ( Site 0087) | Greenville | South Carolina | 29607 | — |
| The University of Tennessee Medical Center ( Site 0116) | Knoxville | Tennessee | 37920 | — |
| Texas Oncology - Dallas (Presbyterian)_McIntyre ( Site 0098) | Dallas | Texas | 75231 | — |
| Texas Oncology - Dallas (Sammons) ( Site 0093) | Dallas | Texas | 75246 | — |
| MD Anderson Cancer Center ( Site 0100) | Houston | Texas | 77030 | — |
| Millennium Research & Clinical Development ( Site 0143) | Houston | Texas | 77090 | — |
| Providence Regional Cancer Partnership ( Site 0106) | Everett | Washington | 98201 | — |
| Medical Oncology Associates, PS ( Site 0142) | Spokane | Washington | 99208 | — |
| Multicare Institute For Research And Innovation ( Site 0108) | Tacoma | Washington | 98405 | — |
| Virginia Mason Memorial- North Star Lodge Cancer Center ( Site 0112) | Yakima | Washington | 98902 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 152 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04624204, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 24, 2026 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04624204 live on ClinicalTrials.gov.